Samsung BioLogics, a global biopharmaceutical CDMO based in South Korea, will transfer assets of Samsung Bioepis to Biogen. Under an asset transfer deal, Samsung BioLogics will transfer 9,226,068 shares of Samsung Bioepis to Biogen on November 7th, for approximately$677 million.    With Biogen’s call option payment, Samsung BioLogics’ cash asset reserve will increase from 477.9 billion won as of end-June 2018 to approximately 1.24 trillion won. The firm’s debt ratio will also be reduced from 9...